Jasper Therapeutics (JSPR) is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback